Three months ago Biogen did something it had not done in years: it told investors the top line would grow. Management flipped its full-year revenue outlook from a mid-single-digit decline to a mid-single-digit increase, closed the Apellis acquisition and secured approvals for high-dose Spinraza and the subcutaneous initiation option for Lekembe. The third-quarter report, due before the open on October 28, is the first real chance to see whether that turn holds up once the deals and launches are running for a full quarter.
The headline numbers will look ugly, and that is by design. Analysts expect earnings of $2.10 a share, down about 56% from $4.81 a year ago, on revenue of roughly $2.59 billion, up only about 2%. The earnings collapse largely reflects what management flagged last quarter when it reset full-year non-GAAP EPS guidance to $12 to $13 from an earlier $15.25 to $16.25 framework. Roughly $3 of that gap comes from in-process R&D and milestone charges, and another $0.85 from financing the Apellis purchase, which pushed net debt to $6.8 billion and adds $120 million to $130 million a year in interest drag. The underlying business, by management's own math, was actually raised by about $0.60. The whisper number of $2.39 sits meaningfully above consensus, suggesting the market suspects charges or costs will land lighter than modeled.
The revenue estimate deserves a closer look. At $2.59 billion, consensus is below the $2.74 billion Biogen posted in the second quarter, even though this period includes a full three months of Cyfovry and Empaveli rather than the partial stretch after the May 14 close. That looks like a cautious bar, likely baking in continued erosion in legacy multiple sclerosis drugs from Tecfidera generics and Tysabri biosimilar pressure, plus inventory swings like the one that knocked Vumerity down 7% last quarter. If the growth portfolio, which topped $1 billion in the second quarter and rose 24% from a year earlier, keeps compounding, revenue has room to clear that hurdle.
The specific evidence that would validate the story is fairly clear. Management described high-dose Spinraza conversion as running much faster than expected, with some patients returning to the drug, so Spinraza trends should show it. Lekembe grew 15% to $184 million last quarter, a sharp slowdown from the 74% pace in the first quarter, and the subcutaneous initiation option only became available at the end of August; early uptake commentary matters more than the quarter's dollars. Skyclarus has been accelerating, and Cyfovry posted its best month ever in June, so continued strength there would support the guidance for mid-to-high teens growth from the Apellis franchise through 2028. Any reaffirmation or nudge higher of the full-year revenue outlook would confirm the inflection; a step back would undercut it quickly.
The market has already started to buy the narrative. Shares are up nearly 11% since the last report, beating the S&P 500 by about 7 points, and at $233.48 the stock trades well above its 200-day moving average of about $198 and just over 3% below its post-earnings high of $240.99. Sentiment has warmed noticeably, moving from clearly bearish heading into last quarter to roughly neutral now. That means the easy skepticism is gone, and a merely adequate quarter may not be enough to push through recent highs.
The central question is whether the growth portfolio is now large and fast enough to outrun legacy MS decline without help from accounting optics. If Spinraza, Lekembe and the newly consolidated Apellis drugs deliver and the revenue guide holds or rises, the noisy EPS line will be easy to look past. If launch momentum stalls, investors will be left staring at a heavier balance sheet and a shrinking earnings figure with less to explain it away.